October 21, 2021
- Controls in Flow Cytometry
- The Cost of Delay: Quantifying the Financial Impact of Inefficient Clinical Trial Start-Up
- TD2 Routine Analysis and More
- Specimen Stability Considerations During Flow Cytometry Assay Development, Optimization and Validation
- Fluorescent Cell Barcoding Using Flow Cytometry For High Throughput Testing
The Cost of Delay: Quantifying the Financial Impact of Inefficient Clinical Trial Start-Up
Clinical trial start-up delays are not just operational hurdles—they can result in significant financial losses. In oncology trials, where timelines ...
TD2 Routine Analysis and More
By Jennifer J. Stewart, PhD
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
